StockWatch
·

Tega Industries Ltd Q1 FY27 Results

TEGAQ1 FY27 Results
Filing
Result:Weak· Market: Up#One-off hit#Margin squeeze#Base effect

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q4 FY26Q1 FY26
Revenue1.7K227.2%384.0%
Total Income1.7K209.1%368.4%
Expenditure1.9K273.9%463.5%
PBT-117.35276.9%380.3%
Net Profit-108.25353.7%406.4%
OPM3.22%8.20pp12.39pp
NPM-6.22%13.80pp15.73pp
EPS11.47101.9%116.0%
View full financials

Reported consolidated net loss with EBITDA margin collapsing to ~4% from 15.6% YoY (driven by a one-off ₹191 Cr Molycop deal charge plus a debt-funded jump in finance costs), missing street estimates despite the standalone pre-Molycop business staying healthy (+18.3% PAT YoY).

TEGA INDUSTRIES · Q1 FY27 · THE VERDICT

₹260 crore of solid EBITDA hides the ₹108 crore path to profitability

Revenue exploded 384% to ₹1,723 crore on Molycop acquisition, but net loss of ₹108.3 crore reflects ₹190 crore in one-time integration costs and ₹110–120 crore annualized finance charge. Underneath, adjusted EBITDA of ₹260 crore (15% margin) is solid—legacy Tega beat margin guidance—and the real story is whether Molycop cross-sell synergies materialize in Q3–Q4.

20 Aug 2026 · 6 min read
Reported Revenue

₹1,723 Cr

+384% YoY; Molycop ₹1,290 Cr (1 month)

Reported Net Loss

-₹108.3 Cr

NPM -6.2%; significant swing from prior-year profit

Adjusted EBITDA

₹260 Cr

15% margin; solid underlying operations

The headline tells one story—revenue exploded on the Molycop acquisition (effective 1 June). But the profit line tells another. A net loss of ₹108.3 crore looks catastrophic on the surface. Underneath lie two separate realities: ₹190 crore in one-time acquisition and integration costs booked in Q1, and an annualized finance burden of ₹110–120 crore from servicing the acquisition debt. Peel both away, and adjusted EBITDA of ₹260 crore (15% margin) is solid. Legacy Tega's consumables business beat margin guidance. The quarter is not a collapse; it is a transition.

Where the net loss came from

Net loss of ₹108.3 crore breaks down as: adjusted EBITDA ₹260 crore, minus ₹190 crore in one-time acquisition and integration costs, minus an estimated ₹110–120 crore annualized finance charge (pro-rated to Q1 ≈ ₹27–30 crore), minus tax and depreciation. The ₹190 crore is not a quarterly run-rate cost. Management confirmed on the call this was the catch-all for Q1 integration. However, disclosure of a prior-quarter estimate of ₹70–80 crore, plus this quarter's ₹190 crore, signals total acquisition drag of roughly ₹265 crore across FY-2027—well above initial guidance of ₹110 crore.

Q1 FY27 profit bridge, ₹ Cr
-244-58128314260Adj. EBITDA-190One-time costs-28Finance (Q1 pro-rata)-150D&A, tax, other-108Reported PAT
The ₹190 crore one-time is Q1-specific; finance costs are structural and annualized. Adjusted EBITDA reflects solid underlying operations.
Management claims vs. what holds up

Strong quarterly performance with margin expansion

What the numbers show

Adjusted EBITDA solid (15%), but net loss ₹108.3 Cr due to ₹190 Cr one-time costs + finance burden

Verdict

Supported operationally; profit distorted by one-time

Legacy Tega EBITDA margins improved to 22.1% from 19.1%

What the numbers show

Legacy Tega ₹435 Cr revenue (+23% YoY); EBITDA margin 22.1%; consumables ₹400 Cr (+36%), margin 24.1%

Verdict

Fully supported; beat FY26 guidance (22%)

Molycop contributed ₹1,290 Cr revenue in June (1 month)

What the numbers show

Molycop June-only revenue ₹1,290 Cr, EBITDA ₹160 Cr (13% margin); 12-month volume -1.6% YoY

Verdict

Supported; volume contraction masked

Equipment shortfall due to customer clearance delays

What the numbers show

Equipment ₹36 Cr vs ₹64 Cr prior year (-44%); EBITDA breakeven; acknowledged temporary

Verdict

Supported; reversal timing unclear

Order book ₹12.3 Cr provides 1-year visibility

What the numbers show

Legacy Tega order book ₹12.3 Cr, ₹9.6 Cr executable within 1 year; Molycop order book not disclosed

Verdict

Partial; Molycop opaque

What changed on this call

Three material moves: (1) Goodwill of ₹50 crore (USD 528 million, provisional) on Molycop, subject to finalization within 1 year per IND-AS 103—a write-down risk if Molycop EBITDA slips below ₹1.6 crore/month. (2) Net debt deleveraged ₹32.18 crore (USD 340 million) this quarter via refinancing and equity support, reducing leverage post-acquisition. (3) Cross-sell synergies deferred to Q3–Q4 onwards ('request couple quarters patience,' per MD); teams still 'getting together' on strategy, meaning momentum is not yet reflected in FY-2027 guidance.

How the street is reading it: The stock rose +2.05% on day 1 and +3.86% by day 3 post-announcement, confirming the market initially valued acquisition upside over the reported loss. However, RSI now sits at 85.7 (overbought), and the stock trades 14.33% off its all-time high despite holding above 20-day and 50-day moving averages. Foreign institutional investors hold steady at 2.80% (up 0.66pp QoQ), while domestic institutions dipped to 18.68% (down 0.28pp). Promoters unmoved at 67.50%. The tape says the market has priced in acquisition hope, but momentum is showing fatigue.

The bull-bear ledger
  • Molycop >50% regional market share in grinding media; monthly EBITDA ₹160 Cr run-rate

  • Legacy Tega beat FY-2026 EBITDA margin guidance (22.1% vs 22% target)

  • Consumables +36% YoY, 24.1% EBITDA margin; 15% CAGR reaffirmed

  • Mining cycle tailwind: copper +4.8% CAGR, gold +2.2% CAGR; supply constraints favor pricing

  • Net debt reduced ₹32.18 Cr; liquidity strengthened post-refinancing

  • Reported net loss ₹108.3 Cr distorts underlying adjusted EBITDA ₹260 Cr (solid)

  • One-time integration costs ₹190 Cr in Q1; ₹75–80 Cr more expected (total ~₹265 Cr)

  • Molycop volumes down 1.6% YoY; pricing power capped by 85% steel-indexed contracts

  • Equipment revenue -44%, breakeven EBITDA; customer clearance delays lack reversal visibility

  • Cross-sell synergies deferred to Q3–Q4; teams still 'getting together' on strategy

  • Finance cost ₹110–120 Cr FY27 structural; offsets ~40% of adjusted EBITDA, limits net profit

  • Goodwill ₹50 Cr provisional; material write-down risk if Molycop EBITDA < ₹1.6 Cr/month

Risks, ranked by how much they should concern a holder

Goodwill impairment risk (₹50 Cr provisional)

High

IND-AS 103 goodwill subject to finalization within 1 year. Material write-down if Molycop EBITDA < ₹1.6 Cr/month sustained or synergy expectations unmet. Masks downside leverage.

One-time integration cost backlog (₹265 Cr total expected)

High

₹190 Cr in Q1; ₹75–80 Cr more expected in FY-2026 close-out. Drag extends Q2–Q3, depresses near-term earnings visibility. Total drag ₹265 Cr vs ₹110 Cr initial guidance.

Net loss despite positive EBITDA (earnings quality)

High

₹260 Cr adjusted EBITDA vs -₹108 Cr net profit. Gap widens from ₹190 Cr one-time + ₹110–120 Cr finance cost. Debt burden materially impairs equity profitability.

Molycop volumes down 1.6% YoY; pricing power hedged to steel indices

Medium

12-month volume 1.204M tons (June) vs 1.223M tons prior year, despite 'ahead of expectations' talk. ~85% contracts steel-indexed limits margin expansion.

Equipment revenue collapsed 44%; reversal timing unclear

Medium

₹36 Cr vs ₹64 Cr prior year. EBITDA breakeven. Customer clearance delays cited but no visibility on order conversion or Q2–Q3 ramp. Equipment miss impacts portfolio mix.

Cross-sell synergies deferred to Q3–Q4; execution unproven

Medium

Mehul said 'Q3–Q4 onwards,' not immediate. Teams 'getting together' to finalize markets and strategy. Deferred ramp = no tailwind in FY-2027 guidance; execution risk if timing slips.

Finance cost burden ₹110–120 Cr FY27 (structural)

Medium

Annualized finance cost offsets ~40% of adjusted EBITDA. Even without one-time costs, net profit limited. Debt USD 672.5 million material post-deleveraging.

Mining cycle cyclicality; copper/gold market softening scenario

Medium

Molycop's per-ton margins depend on mining capex cycle and commodity volatility. No pricing power if capex cycle flips or Chinese competition intensifies in LatAm.

What to watch next
  • 1 · Q3 or Q4 cross-sell revenue ramp

    Management promised 'Q3–Q4 onwards' for cross-sell synergies. Watch for Molycop equipment penetration into Tega customer base and vice versa. If deferred past Q4 or fails to materialize, execution risk crystallizes and FY-2028 growth is at risk.

  • 2 · Molycop EBITDA margin sustainability & volume recovery

    June 1-month EBITDA ₹160 Cr (13% margin) is the baseline. Monitor whether volumes recover (currently -1.6% YoY) and whether steel-indexed pricing remains stable. If margin compresses below 12% or volumes decline further, goodwill impairment becomes probable.

  • 3 · Chile plant commissioning (Jan soft, March commercial)

    Management guided soft commissioning January 2027, commercial production March 2027, subject to regulatory approvals. Delays in commissioning are a downside risk. Successful ramp adds meaningful EBITDA capacity post-Q4 FY-2027; misses delay margin recovery.

  • 4 · Net debt trajectory and refinancing headroom

    Debt reduced ₹32.18 Cr this quarter, but USD 672.5 million remains material. Watch quarterly debt paydown and whether non-core asset sales proceed as planned. If mining cycle softens, refinancing risk and covenant tightness could limit capex flexibility.

  • 5 · Equipment order conversion and legacy Tega margin durability

    Equipment -44% needs to stabilize by Q2–Q3. Meanwhile, Tega consumables 24.1% EBITDA margin is the steady-state; ability to pass through commodity inflation via ~1-quarter lag is key to maintaining guidance.

Tega's Q1 is not a quarter-to-quarter blow; it is a pivot. Revenue exploded on acquisition; profit is depressed by one-time costs and a heavy finance burden that is structural, not temporary. Underneath, legacy Tega beat margin guidance and consumables momentum is real. This is an acquisition integration story, not an organic growth inflection. Returns from here depend on Molycop cross-sell synergies and Chile plant upside—both deferred to Q3–Q4 or later. Promoters hold firm at 67.50%, FII steady at 2.80%, but RSI at 85.7 signals the market has priced in hope. Hold for the next two quarters—cross-sell momentum in Q3–Q4 is the make-or-break catalyst.

The single number to track from here: whether Q3–Q4 consolidated EBITDA sustains the ₹260 crore run-rate (confirming Molycop cross-sell impact). If it does, synergies are real and goodwill is safe. If it stalls, impairment risk and downside repricing follow.

Informational and educational content only. Not investment advice.